Tuberculosis persists despite preventive therapy in HIV patients
A study from Mozambique investigates the incidence of tuberculosis in people living with HIV who have recently started antiretroviral therapy and received TB preventive therapy. The research, published by the CDC, highlights a critical gap in long-term protection, suggesting that immune reconstitution following ART initiation may not fully restore protective immunity against Mycobacterium tuberculosis. This finding underscores the complex interplay between antiviral treatment, immune system recovery, and persistent susceptibility to co-infections.
Why it might matter to you: For professionals focused on immunology and infectious diseases, this study directly addresses the failure of adaptive immunity in a high-risk, immunocompromised population. It highlights a crucial real-world scenario where T-cell mediated immunity and immune memory are insufficient, pointing to a need for more robust vaccine strategies or adjunctive immunotherapies. Understanding these immune evasion mechanisms is fundamental to developing next-generation interventions for global health challenges like TB/HIV co-infection.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
